• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic’s Covidien to pay $20m to settle ClosureFast kickback allegations

Medtronic’s Covidien to pay $20m to settle ClosureFast kickback allegations

March 13, 2019 By Fink Densford

Medtronic logo updated

Medtronic‘s (NYSE:MDT) Covidien has agreed to pay approximately $20 million to resolve kickback allegations related to the sale and promotion of its ClosureFast radiofrequency ablation catheters.

The Fridley, Minn.-based company agreed to pay approximately $17.5 million to the U.S. to settle alleged violations of the False Claims Act and an additional $1.5 million to California and $1 million to Florida for claims settled by state Medicaid programs, according to a U.S. Department of Justice release.

“Today’s settlement serves as an important reminder to those in the health care community that unlawful kickbacks come in many forms and are not limited to monetary payments to providers. Providing free or discounted services to health care providers to induce the use of certain items or services can lead to excessive and unnecessary treatments, and drive up health care costs for everyone,” DoJ Civil Division Assistant Attorney General Jody Hunt said in a prepared statement.

In the case, the DoJ alleged that Covidien illegally supplied practice development and market development support to healthcare providers in California and Florida to promote the use and purchasing of its ClosureFast radiofrequency ablation catheters.

The allegations include claims that Covidien provided customized marketing plans, scheduled and conducted “lunch and learn” meetings and dinners and engaged in other free or discounted services to promote the use of its ClosureFast device.

The ClosureFast catheters, which are intended for use in treating venous reflux disease, were billed to Medicare and to the California and Florida Medicaid systems, according to the DoJ release.

“The government contended that Covidien provided discounted or free services to health providers – and so hoped to evade kickback charges. Companies seeking to buy clients through such arrangements can expect to pay a steep price,” Dept. of Health and Human Services Special Agent In Charge for the Office of Inspector General Steven Ryan said in a press release.

“Kickback schemes don’t just victimize those directly involved, they undermine the public’s trust in our healthcare system and drive up costs for everyone. This significant settlement sends a clear message: healthcare providers who engage in this kind of activity and put their own greed before the needs of their patients will be aggressively pursued by the FBI and our federal partners,” FBI San Francisco Special Agent in Charge John Bennett said in prepared remarks.

Since December, the medical giant has agreed to pay a total of $50.9 million to settle a number of probes into marketing activities from ev3 and Covidien, including $17.9 million in an ev3-related off-label marketing case.

Filed Under: Business/Financial News, Featured, Legal News Tagged With: Covidien, Medtronic

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy